The SCN acts as the central pacemaker for circadian rhythms in mammals. Histamine has been shown to affect circadian rhythms both in vivo and in vitro. We investigated the mechanism by which histamine phase shifts circadian rhythms in vitro. Hypothalamic slices containing the SCN were prepared from golden hamsters, and spontaneous firing rates of individual cells were recorded on the second day in vitro. Application of histamine (1 µM -10 mM) at the extrapolated time of 2 h after lights off (ZT 14) on day 1 in vitro delayed the time of peak firing in a dose-dependent manner. Pre-exposure to the N-methyl-Daspartate (NMDA) receptor antagonist (±)-2-amino-5-phosphonopentanoic acid (AP-5; 100 µM -1mM) 5 min before histamine (1 µM) was applied to the slice blocked the phase-delaying effects of histamine. Application of the H1 blocker mepryamine (100 nM) or the H2 blocker cimetidine (10 µM) followed by histamine had no effect on the phase delay induced by histamine. In whole cell recordings from acutely dissociated neurons of hamster SCN, histamine (50 µM) was shown to potentiate NMDA-evoked currents by 52 ± 12%. These experiments demonstrate that histamine phase shifts of the circadian clock are dependent on NMDA receptor activation and that histamine can directly potentiate NMDA currents in SCN neurons. Histamine may alter circadian clock function by acting directly on NMDA receptors, possibly via binding to the polyamine site.
INTRODUCTION
Circadian rhythms are daily oscillations in behavior, endocrinology, biochemistry, and physiology. Mammalian rhythms are predominantly driven by an endogenous pacemaker consisting of a group of neurons and glia located in the hypothalamic SCN (Reuss, 1996; Rusak and Zucker, 1979) . Rhythmicity is synchronized to the LD cycle, with light pulses in the early subjective night delaying the phase of the pacemaker and pulses in the late subjective night advancing the pacemaker 's phase (Daan and Pittendrigh, 1976) . Photic information is conveyed directly to the SCN via the retinohypothalamic tract. Glutamate release from retinal fibers may mediate photic phase shifts via both N-methyl-D-aspartate (NMDA) and non-NMDA receptors (Colwell and Menaker, 1992; Ebling, 1996) .
While the photic phase-shifting pattern can be mimicked in vivo by micro-injection of NMDA into the SCN (Mintz and Albers, 1997) , a similar pattern is also produced by intraventricular injections of histamine (Itowi et al., 1990) . Histamine is a neurotransmitter implicated in the control of sleep and arousal (Sherin et al., 1996; Wada et al., 1991) . Most histaminergic neurons are located in the posterior basal hypothalamus in the tuberomammillary complex (Ericson et al., 1987; Panula et al., 1989) , and histaminergic projections have been shown to terminate in the SCN of rats, guinea pigs (Airaksinen and Panula, 1988; Ingaki et al., 1988; Panula et al., 1989) , and hamsters (P. Panula, personal communication) . A daily pattern in histamine release in the anterior hypothalamic area has been observed in rats housed under an LD cycle (Mochizuki et al., 1992) . In vivo studies have also shown that depletion of brain histamine levels by inhibition of histamine synthesis reduces light-pulseinduced phase shifts in circadian rhythms of hamster wheel-running activity (Eaton et al., 1995) . Histamine does not appear to induce this effect through any of the three major histamine receptor subtypes, H1, H2, or H3 (Eaton et al., 1996) despite the large number of H1 binding sites found in the rat SCN (Palacios et al., 1981) . The histamine-induced photic phase-shifting pattern has also been demonstrated in vitro using the hamster SCN brain slice preparation (Cote and Harrington, 1993) . Furthermore, both excitatory and inhibitory responses of SCN neurons to histamine applications have been recorded in the rat SCN brain slice in vitro (Liou et al., 1983; Stehle, 1991) .
Several investigators have demonstrated that histamine potentiates currents evoked by the activation of NMDA receptors in hippocampal and cortical neurons (Bekkers, 1993; Payne and Neuman, 1997; Vorobjev et al., 1993; Yanovsky et al., 1995) . They suggest that histamine modulates the NMDA response by binding to the polyamine site on the NMDA receptor-complex. However, potentiation of NMDA responses in cortical neurons was shown to be partially mediated by histamine's action at the H1 receptor (Payne and Neuman, 1997) .
In the following study, we have addressed the mechanism by which histamine mediates its photic pattern of phase shifting of the firing rate in the hamster SCN brain slice preparation. Using patch-clamp, we show that in SCN neurons, histamine potentiates NMDA responses, and we describe how histamine phase shifts in the slice preparation are dependent upon NMDA receptor activation.
MATERIALS AND METHODS

Brain Slice Preparation
Male golden hamsters (Charles River Labs, 3-12 wk) were housed in a 24-h LD cycle with 14 h of light. ZT 12 was arbitrarily defined as the onset of the dark cycle. Hamsters were overdosed with halothane and decapitated between ZT 4 and ZT 9. Coronal hypothalamic slices (400 µM) containing the SCN were prepared. Slices were maintained at the interface between warm humidified gas (95% O 2 : 5% CO 2 ) and artificial cerebrospinal fluid (ACSF; 125.2 mM NaCl, 3.8 mM KCl, 1.2 mM KH 2 PO 4 , 24.8 mM NaHCO 3 , 10 mM Dglucose, 1 mM MgSO 4 , 1.8 mM CaCl 2 , 50 mg/l gentamicin and 2 mg/l amphotericin, pH 7.4, 34.5ºC, 1 ml/min). All chemicals were supplied by Sigma unless otherwise stated.
Drugs were either applied as 200nl microdrops, placed directly on the SCN or by bath application. The first microdrop was either the NMDA antagonist, (±)-2-amino-5-phosphonopentanoic acid (AP-5; 100 µM or 1 mM, Research Biochemicals, Inc.), or a control ACSF application at ZT 14 on the first day in vitro. This was followed 5 min later by a microdrop application of either histamine (10 nM -10 mM) or ACSF. The H1 receptor antagonist, mepyramine (100 nM or 1 µM, Research Biochemicals, Inc.), or the H2 antagonist, cimetidine (10 µM, Research Biochemicals, Inc.) was applied via a 2 h bath application between ZT 13 and ZT 15 on the first day in vitro during which, at ZT 14, a microdrop of either histamine (1 µM) or ACSF was applied. Extracellular single-unit activity was recorded during the second day in vitro using a glass micropipette electrode filled with NaCl (2 M) or ACSF. Electrodes were visually placed above the SCN with a dissecting microscope and were lowered through the tissue using a hydraulic microdrive until a cell was encountered. Each cell's spontaneous firing rate was measured for 1 min, and the average firing rate of a cell was plotted against ZT. Recordings from individual slices were generally conducted for 5-9 h between ZT 3 and ZT 12 on the second day in vitro with the recorder blind to the experimental condition. Only results from slices in which there was a significant difference across 1 h bins (analysis of variance [ANOVA], p < .05) were used for further analysis. Data were analyzed using a 1-h running mean smoother with a 15-min lag, and the time of peak firing rate was calculated as the ZT at the middle of the 1-h bin with the highest value. Groups were compared with the one-way ANOVA, with pairwise multiple comparisons via the Student-Newman-Keuls method (Sigma Stat software; significance set to p < .05). Separate analyses were performed for histamine dose-response experiments and for receptor antagonist (AP-5, mepyramine) experiments.
We noted that in taking coronal brain slices from an individual hamster, several slices contained SCN tissue. As part of our ongoing efforts to reduce the number of animals used in these experiments, in some cases we simultaneously recorded from two slices taken from one hamster. In these cases, the two slices were treated differently in terms of drug applications, so that the data in any one experiment always represent results from slices from different individuals.
Patch-Clamp Experiments
SCN neurons were acutely dissociated from brain slices of 6-to 14-day-old golden hamster pups. Animals were sacrificed with an overdose of halothane followed by decapitation and removal of the brain into cold ACSF. Hypothalamic slices (500-750 µm) containing the SCN were prepared and placed in ACSF bubbled with 95% O 2 : 5% CO 2 for 30-45 min at room temperature. SCN were then carefully cut out from the tissue with a razor blade, chopped into 3-4 small pieces, and placed in a protease solution (Type XIV, Bacterial Streptomyces griseus, Sigma, 1.5 mg/l ml ACSF) at 37ºC for 5-6 min. The tissue was then washed twice in protease-free HEPES-buffered minimum essential medium (MEM, Sigma). Individual pieces of tissue were dissociated by trituration in 200-300 µl of MEM with a fire-polished pipette. The resultant cell suspension was placed in a bath filled with extracellular solution (see below) and allowed to settle for 10 min prior to recording. Remaining pieces of tissue were incubated at room temperature in MEM bubbled with 95% O 2 : 5% CO 2 and were viable for up to 3 h for subsequent plating and recording. Predominantly unipolar and bipolar SCN neurons of 5-10 µm diameter were identified by size and morphology (Ito et al., 1991) .
Dissociated neurons were recorded in standard whole-cell patch configuration (Hamill et al., 1981) using borosilicate glass pipettes fabricated by a twostage pull (Narishige, PB-7) and filled with the intracellular solution: 5 mM KCl, 125 mM Kgluconate, 5 mM EGTA, 0.5 mM CaCl 2 , 2 mM Na 2 ATP, 2 mM MgCl 2 , 0.4 mM Na 3 GTP, 10 mM HEPES, pH to 7.3 w/KOH, giving typical resistances of 3-6 MΩ. All cells were bathed in an extracellular saline (140 mM NaCl, 2.5 mM KCl, 3 mM CaCl 2 , 3 mM Glucose, 10 mM HEPES with 1 µM Glycine, pH to 7.3 with NaOH) at a rate of 1 ml/min. Drugs (50 µM histamine, 100 µM NMDA, 100 µM AP-5) were introduced using a local rapid superfusion system whereby control or drug solutions could be applied individually through one of a pair of fused glass tubes (700 µm in diameter) positioned 600 µm from a chosen neuron. The tubes could be translated hydraulically so that the solution bathing the neuron was rapidly switched from one composition to another. Cells were held at either -50 or -60 mV, and currents were acquired using an Axoclamp 200A (Axon Instruments) interfaced to a computer running pClamp 6.1 software (Axon Instruments). Data were filtered at 50 Hz with a low-pass Bessel filter (Fylde, Preston, UK), sampled at 400 Hz and analyzed using pClamp6.1. NMDA applications were all separated by at least 2 min to allow sufficient time for recovery from receptor desensitization. In calculating percentage potentiation by histamine of NMDA responses, peak currents were averaged from control NMDA responses before and after exposure to NMDA solutions including histamine. Similarly, for assessing inhibitions to AP-5, control currents were averaged from NMDA responses before and after AP-5 exposure. Values are given as mean ± SEM.
RESULTS
Effect of Histamine in Brain Slice Experiments
In control experiments (ACSF treated or untreated slices), the spontaneous firing rate of SCN neurons peaked at ZT 6.1 ± 0.2 h (n = 5) on the second day in vitro. A microdrop application of 10 nM histamine at ZT 14 on the first day in vitro had no significant phase-shifting effect on the peak firing time of SCN neurons (mean ± SEM phase shift: -0.2 ± 0.2, n = 3). At 1 µM -10 mM, histamine phase-delayed the peak (see Figs. 1 and 2) in a dose-dependent manner. At 1 µM, histamine caused a 2.4 ± 0.4 h (n = 6) delay; at 100 µM, histamine application resulted in a significantly greater delay of 4.8 ± 0.2 h (n = 3). We conducted two experiments with applications of 10 mM histamine, and in both cases the phase shift was smaller than that after application of 100 µM histamine (average delay: 2.4 ± 0.8 h, n = 2), suggesting an inverted-U shaped dose-response curve.
When the SCN were pre-exposed to AP-5 (1 mM) and then histamine (1 µM), the recorded peak time was ZT 6.1 ± 0.2, which was not significantly different from the peak for control slices (mean ± SEM phase shift: -0.01 ± 0.2 h, n = 5; see figs. 1 and 2). AP-5 (1 mM) consistently blocked the phase-delaying effects of histamine, without having any effect on the peak time when applied alone (mean ± SEM phase shift: -0.1 ± 0.1 h, n = 3). When AP-5 was applied at a lower dose (100 mM), the histamine-induced phase shift was significantly blocked (mean ± SEM phase shift: -1.0 ± 0.6 h, n = 5). However, this 100 µM AP-5 block was vari-able; in some cases, the shift was entirely blocked (mean ± SEM phase shift: 0.2 ± 0.2 h, n = 3), whereas in other cases it was not blocked at all (mean ± SEM phase shift: -2.4 ± 0.2 h, n = 2). The time of peak firing from the slices that received AP-5 (100 µM) alone at ZT 14 (mean ± SEM phase shift: 0.4 ± 0.6 h, n = 3) was not significantly different from untreated or ACSF treated controls.
In a previous study (Cote and Harrington, 1993) , bath-applied histamine (1 µM) produced similar phase delays in time of peak activity in the hamster SCN brain slice and the H1 antagonist mepyramine at 1 µM blocked this shift when co-applied. Similarly, we found that 1 µM mepyramine blocked the histamineinduced phase shift in one case (phase shift: 0.2 h), but not in three other similarly treated slices (mean ± SEM phase shift: -2.1 ± 0.02 h; group average ± SEM phase shift: -1.5 ± 0.6, n = 4). A lower and more specific (see Discussion) dose of mepyramine (100 nM) did not block the histamine-induced phase shift (mean ± SEM phase shift: -2.2 ± 0.1 h, n = 3; Fig. 2 ) and had no effect on the time of peak firing (mean ± SEM phase shift: 0.1 ± 0.1 h, n = 3) when applied alone.
Similarly, the H2 antagonist, cimetidine (10 µM) did not effectively block the histamine-induced phase shift (mean ± SEM phase shift: -2.3 ± 0.2 h, n = 3; Fig. 1 ) and had no effect on the time of peak firing (mean ± SEM phase shift: -0.6 ± 0.1 h, n = 3) when applied alone.
Effect of Histamine on NMDA Receptor Currents from SCN Whole-Cell Recording
To investigate a potential underlying mechanism for the histamine effect in the slice preparation, we conducted whole-cell patch clamp experiments on dissociated hamster SCN neurons. Upon establishing the whole-cell configuration, cells were routinely held at -50 to -60 mV. Rapid switches into a solution containing 100 µM NMDA consistently produced inward currents of 55.0 ± 12 pA at -50mV (n = 6; Fig. 3A ). When histamine (50 µM) was co-applied with the NMDA (100 µM), currents were often potentiated (n = 9 cells; Fig. 3A ), although occasionally cells showed no enhancement of peak inward current (not shown, n = 3). The extent of the histamine potentiations varied considerably between cells (13%-132%) with an average of 52 ± 12% (mean ± SEM, n = 9). Applications of histamine (50 µM) alone did not evoke any current responses in all cells tested (n = 4, not shown). In the presence of AP-5 (100 µM; Fig. 3B ), the histamine-potentiated NMDA currents were largely inhibited (88 ± , n = 5 or 1 mM, n = 3), mepyramine (100 nM, n = 3) , or cimetidine (10 µM, n = 3). Phase delay shifts are shown as negative values, whereas phase advance shifts are shown as positive values relative to the mean peak time for control slices. Phase shifts following treatments with AP-5 (100 µM and 1 mM) alone or AP-5 followed by histamine did not differ from controls. Phase shifts measured following combined mepyramine (100 nM) and histamine treatments or combined cimetidine (10 µM) and histamine treatments were not significantly different from histamine treatments alone. 5%, n = 4) and recovered after AP-5 washout (n = 4, not shown).
DISCUSSION
Histamine applied as a microdrop at ZT 14 on the first day in vitro delayed the time of peak of the hamster SCN firing rate rhythm on the second day in vitro in a dose-dependent manner, with no effect at 10 nM and maximal effect at 100 µM (ca. 5-h delay). These results are similar to our previous report (Cote and Harrington, 1993) where bath-applied histamine at ZT 14 induced phase delays. Our previous work also showed that histamine applied at ZT 20 induced phase advances of the firing rate rhythm, whereas application of histamine during the subjective day (ZT 6) had no effect on the phase of the rhythm (Cote and Harrington, 1993) . This pattern of phase shifts is similar to that for glutamate applications to the rat (Ding et al., 1994; Shirakawa and Moore, 1994a) and hamster (Biello et al., 1997 ) SCN in vitro. Therefore, our results, along with in vivo studies of intraventricular injections of histamine (Itowi et al., 1990) , confirm that the magnitude and direction of the phase-shifting effects of histamine depend on circadian phase in a manner similar to light.
Depletion of brain histamine reduces the magnitude of light-induced phase shifts (Eaton et al., 1995) , indicating a role for histamine in the circadian clock response to light. On the other hand, blockade of either H1, H2, or H3 receptors had no effect on light-induced phase shifts (Eaton et al., 1996) . We now show that histamine phase shifts in vitro can be blocked by prior treatment of the SCN with AP-5, a specific blocker of the NMDA excitatory amino acid receptor. This result suggests that histamine mediates its effects on the clock via a mechanism that involves NMDA receptor activation. Activation of the H1 receptor can be partially responsible for potentiation of NMDA responses in mammalian neurons (Payne and Neuman, 1997) . Therefore, we examined the effect of mepyramine, a high affinity (K d ~ 0.8 nM; Hill, 1992) H1 antagonist, on the histamine-induced phase shift. At a dose of 1 µM, mepyramine could block the histamine-induced delay, as previously reported (Cote and Harrington, 1993) , although this block was observed in only one of the five cases in the present experiment. However, at a more reasonable dose (100 nM) at which mepyramine is less likely to have nonspecific effects (Hill, 1992) , the histamine-induced phase delay persisted. Therefore, we conclude that histamine is not mediating its effect on NMDA transmission via an indirect action on H1 receptors. This conclusion is consistent with our results from in vivo studies in which H1 receptor antagonists had no effect on lightinduced phase shifts (Eaton et al., 1996) . Similarly, the H2 receptor antagonist, cimetidine, did not block histamine-induced phase shifts. We did not test H3 receptor antagonists since we have not observed any H3 receptors in the hamster SCN (S. L. Yates and M. E. Harrington, unpublished results).
Using whole-cell patch clamp technique, we observed NMDA-activated inward currents from acutely dissociated hamster SCN neurons, as previously reported for rat SCN neurons (Ito et al., 1991) . Histamine (50 µM) potentiated 100 µM NMDA current responses in a similar manner to recordings from rat hippocampal and cortical neurons (Bekkers, 1993; Payne and Neuman, 1997; Vorobjev et al., 1993) . All the SCN whole-cell NMDA/histamine currents were blocked by AP-5. In recordings from rat hippocampus, NMDA receptor-mediated currents were unaffected by 5 µM histamine when the extracellular pH was maintained at 7.4, and significant potentiations were only observed at pH 7.2 (Saybasili et al., 1995; Yanovsky et al., 1995) . Similarly, when using 5 µM histamine with extracellular solutions at pH 7.4, we observed no potentiation of the 100 µM NMDA response (n = 10, not shown).
A recent study indicates that histamine may not shift hamster circadian rhythms in vivo (Scott et al., 1998) . Our results suggest several important considerations for the design of in vivo studies of histamineinduced phase shifts. It would be critical to conduct such studies with a range of histamine doses, since the dose-response curve for histamine's potentiation of the NMDA receptor has an inverted-U shape (Vorobjev et al., 1993) . Thus, a very high dose of histamine might lead to no histamine effect being observed. In addition, the pH of the solution might drastically alter the strength of the histamine potentiation of NMDA currents (Saybasili et al., 1995; Yanovsky et al., 1995) .
Using in vivo microdialysis in the anterior hypothalamic area of freely moving rats under a 12:12 LD cycle, Mochizuki et al. (1992) showed that histamine release begins to increase in the middle of the light period and is maintained at high levels through the dark period. To our knowledge, no one has yet published results from studies of histamine levels in the SCN of animals under DD, or in response to brief light pulses; such studies could distinguish circadian modulation of release from direct photic responses. Evidence points to modulation of histamine release by states of arousal, with highest levels of release occurring during waking (Steriade and McCarley, 1990) . Our results would suggest that light exposure combined with a waking state would produce larger circadian phase shifts than light exposure when sleeping, owing to the potentiation produced by histamine released during waking. Our results also indicate that circadian entrainment abnormalities are to be expected when brain histamine levels are pharmacologically altered.
These results may point to a more general hypothesis for the neurochemical control of clock phase. We hypothesize that other neurochemicals known to reset the mammalian clock in the photic pattern may also act via potentiation of the NMDA receptor. For exam-ple, substance P has been shown to phase shift in the photic pattern (Shibata et al., 1992) and has also been shown to modulate glutamatergic responses of SCN neurons (Piggins et al., 1995; Shirakawa and Moore, 1994b) . In fact, it appears that the more direct test using an NMDA receptor antagonist to attempt to block a substance P-induced phase shift has been attempted and preliminary results suggest that substance P phase shifts are dependent upon NMDA receptor activation (see Shibata personal communication quoted in Shigeyoshi et al., 1997) . Somatostatin is also capable of inducing phase shifts in the photic pattern (Hamada et al., 1993) but to our knowledge has not been tested with co-application of NMDA receptor antagonists. Interestingly, phase shifts induced by carbachol, which are in a pattern sometimes similar to that of light, are blocked by prior treatment with NMDA receptor antagonists in vivo (Colwell et al., 1993) . The NMDA receptor is also involved in responses to excitatory inputs to the SCN. Potentiation of excitatory tone of retinohypothalamic tract (RHT) or other SCN inputs via neuromodulators acting on the NMDA receptor might induce phase shifts of the circadian clock. Since NMDA receptors presumably function to mediate a response to photic input via the RHT, it is plausible that neurotransmitters modulating NMDA receptor activation might alter light-induced phase shifts.
